Trials / Unknown
UnknownNCT02314676
Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 900 (estimated)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 3 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the safety and efficiency of Pegylated Somatropin (PEG Somatropin) Injection in the treatment of endogenous growth hormone deficiency (GHD) in the broad population of children. Half of participants will receive the high dose, while the other half will receive the low dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PEG-somatropin |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2017-07-01
- First posted
- 2014-12-11
- Last updated
- 2014-12-11
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02314676. Inclusion in this directory is not an endorsement.